Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Bristol-Myers Squibb receives approval for Yervoy

Bristol-Myers Squibb receives approval for Yervoy

15th July 2011

Bristol-Myers Squib has been granted European regulatory approval for Yervoy to be utilised as an advanced melanoma therapy among adult patients.

The European Commission has ratified the drug for use among previously-treated patients, based on positive data from phase III trials which underlined its safety and efficacy.

Yervoy is now the only approved therapy for pre-treated unresectable or metastatic melanoma to show significant overall survival benefits, as well as being the first treatment approved for this disease in the EU for more than 20 years.

Bristol-Myers Squibb added that it will be working with local health authorities to expedite its availability via reimbursement schemes.

Ron Cooper, president of Bristol-Myers Squibb Europe, said: "With an average survival time on diagnosis of six to nine months, patients with advanced melanoma have had little hope – until now."

Earlier this month, the company agreed a deal with Innate Pharma to license IPH102, a new oncology compound currently in development as an acute myeloid leukaemia therapy.ADNFCR-8000103-ID-800623028-ADNFCR

We currently have 9 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.